Allogene, Pliant down as J.P. Morgan cuts to Underweight on...

2025-10-10 09:03:44 ET More on Allogene Therapeutics, Pliant Therapeutics Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript Allogene Therapeutics: Important Catalysts Guided For Early 2026 Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances Allogene Therapeutics GAAP EPS of -$0.23 beats by $0.05 Read the full article on Seeking Alpha For further details see: Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook